Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer

被引：5
作者：
Kolarova, Iveta [1 ,2 ]
Dusek, Ladislav [3 ]
Ryska, Ales [4 ,5 ]
Odrazka, Karek [6 ,7 ,8 ,9 ,10 ]
Dolezel, Martin [8 ,11 ]
Vanasek, Jaroslav [2 ,6 ,7 ]
Melichar, Bohuslav [1 ,11 ,12 ]
Petera, Jiri [1 ,12 ]
Buchler, Tomas [8 ,13 ]
Vosmik, Milan [1 ,12 ]
Petrakova, Katarina [14 ]
Terarova, Petra [8 ,15 ]
Vilasova, Zdena [6 ]
Jarkovsky, Jiri [3 ]
机构：
[1] Univ Hosp Hradec Kralove, Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[2] Pardubice Univ, Fac Hlth Studies, Pardubice, Czech Republic
[3] Masaryk Univ, Fac Med, Inst Biostat & Anal, Kamenice 3, Brno, Czech Republic
[4] Charles Univ Prague, Med Fac, Fingerland Dept Pathol, Hradec Kralove, Czech Republic
[5] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic
[6] Multiscan, Oncol Ctr, Pardubice, Czech Republic
[7] Pardubice Hosp, Dept Clin & Radiat Oncol, Pardubice, Czech Republic
[8] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[9] Charles Univ Prague, Fac Med 3, Dept Radiotherapy & Oncol, Prague, Czech Republic
[10] Inst Postgrad Med Educ, Prague, Czech Republic
[11] Palacky Univ, Med Sch & Teaching Hosp, Dept Oncol, Olomouc, Czech Republic
[12] Charles Univ Prague, Fac Med Hradec Kralove, Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[13] Thomayer Hosp, Prague, Czech Republic
[14] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic
[15] Gen Univ Hosp Prague, Dept Oncol, Prague, Czech Republic
来源：
IN VIVO | 2020年 / 34卷 / 06期
关键词：
Breast cancer; triple positive; HER2-positive; hormone receptors; overall survival; trastuzumab; BREAST-CANCER; TRASTUZUMAB; THERAPY; RESISTANCE;
D O I：
10.21873/invivo.12183
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.
引用
收藏
页码：3441 / 3449
页数：9
相关论文
共 21 条
  • [1] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
    Cardoso, F.
    Costa, A.
    Senkus, E.
    Aapro, M.
    Andre, F.
    Barrios, C. H.
    Bergh, J.
    Bhattacharyya, G.
    Biganzoli, L.
    Cardoso, M. J.
    Carey, L.
    Corneliussen-James, D.
    Curigliano, G.
    Dieras, V.
    El Saghir, N.
    Eniu, A.
    Fallowfield, L.
    Fenech, D.
    Francis, P.
    Gelmon, K.
    Gennari, A.
    Harbeck, N.
    Hudis, C.
    Kaufman, B.
    Krop, I.
    Mayer, M.
    Meijer, H.
    Mertz, S.
    Ohno, S.
    Pagani, O.
    Papadopoulos, E.
    Peccatori, F.
    Penault-Llorca, F.
    Piccart, M. J.
    Pierga, J. Y.
    Rugo, H.
    Shockney, L.
    Sledge, G.
    Swain, S.
    Thomssen, C.
    Tutt, A.
    Vorobiof, D.
    Xu, B.
    Norton, L.
    Winer, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 16 - 33
  • [2] Chumsri S, 2019, CANC RES S, V79, DOI [10.1158/1538-7445.SABCS18-PD3- 02, DOI 10.1158/1538-7445.SABCS18-PD3-02]
  • [3] Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
    Colleoni, Marco
    Sun, Zhuoxin
    Price, Karen N.
    Karlsson, Per
    Forbes, John F.
    Thurlimann, Beat
    Gianni, Lorenzo
    Castiglione, Monica
    Gelber, Richard D.
    Coates, Alan S.
    Goldhirsch, Aron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) : 927 - +
  • [4] Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics
    Colzani, Edoardo
    Liljegren, Annelie
    Johansson, Anna L. V.
    Adolfsson, Jan
    Hellborg, Henrik
    Hall, Per F. L.
    Czene, Kamila
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4014 - 4021
  • [5] Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    Giordano, Sharon H.
    Temin, Sarah
    Kirshner, Jeffrey J.
    Chandarlapaty, Sarat
    Crews, Jennie R.
    Davidson, Nancy E.
    Esteva, Francisco J.
    Gonzalez-Angulo, Ana M.
    Krop, Ian
    Levinson, Jennifer
    Lin, Nancy U.
    Modi, Shanu
    Patt, Debra A.
    Perez, Edith A.
    Perlmutter, Jane
    Ramakrishna, Naren
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 2078 - U148
  • [6] Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
    Giuliano, Mario
    Trivedi, Meghana V.
    Schiff, Rachel
    [J]. BREAST CARE, 2013, 8 (04) : 256 - 262
  • [7] Differences in Breast Cancer Survival by Molecular Subtypes in the United States
    Howlader, Nadia
    Cronin, Kathleen A.
    Kurian, Allison W.
    Andridge, Rebecca
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (06) : 619 - 626
  • [8] US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
    Howlader, Nadia
    Altekruse, Sean F.
    Li, Christopher I.
    Chen, Vivien W.
    Clarke, Christina A.
    Ries, Lynn A. G.
    Cronin, Kathleen A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05):
  • [9] Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database
    Kolarova, I
    Vanasek, J.
    Dolezel, M.
    Stuk, J.
    Hlavka, A.
    Dusek, L.
    Melichar, B.
    Buchler, T.
    Ryska, A.
    Prausova, J.
    Petrakova, K.
    Tesarova, P.
    Petera, J.
    Vosmik, M.
    Horackova, K.
    Jarkovsky, J.
    [J]. NEOPLASMA, 2020, 67 (06) : 1373 - 1383
  • [10] Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
    Larionov, Alexey A.
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
123